TESARO, Inc. (NASDAQ:TSRO) – Equities researchers at Wedbush increased their Q3 2017 earnings estimates for shares of TESARO in a research note issued on Wednesday. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will earn ($0.52) per share for the quarter, up from their prior forecast of ($1.65). Wedbush has a “Outperform” rating and a $168.00 price objective on the stock. Wedbush also issued estimates for TESARO’s Q4 2017 earnings at ($2.32) EPS, FY2017 earnings at ($8.20) EPS, Q1 2018 earnings at ($1.56) EPS, Q2 2018 earnings at ($1.26) EPS, Q3 2018 earnings at ($0.92) EPS, Q4 2018 earnings at ($0.57) EPS, FY2018 earnings at ($4.31) EPS, FY2019 earnings at $1.75 EPS, FY2020 earnings at $8.83 EPS and FY2021 earnings at $14.74 EPS.
TESARO (NASDAQ:TSRO) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.52) by $0.30. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The business had revenue of $29.50 million during the quarter, compared to the consensus estimate of $18.61 million. During the same period in the prior year, the company earned ($1.28) earnings per share. The business’s revenue was down 17.6% on a year-over-year basis.
A number of other equities analysts have also weighed in on the stock. Robert W. Baird restated a “neutral” rating and issued a $140.00 price objective (down from $155.00) on shares of TESARO in a report on Thursday. Morgan Stanley restated an “overweight” rating and issued a $183.00 price objective on shares of TESARO in a report on Thursday. ValuEngine upgraded shares of TESARO from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Credit Suisse Group set a $198.00 price objective on shares of TESARO and gave the stock a “buy” rating in a report on Wednesday, July 19th. Finally, BidaskClub lowered shares of TESARO from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. TESARO presently has an average rating of “Buy” and an average target price of $176.35.
TESARO (NASDAQ:TSRO) opened at 110.89 on Friday. The company’s market capitalization is $5.99 billion. The firm’s 50-day moving average price is $131.54 and its 200 day moving average price is $149.39. TESARO has a one year low of $83.26 and a one year high of $192.94.
In other news, VP Edward C. English sold 8,500 shares of the business’s stock in a transaction on Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the completion of the sale, the vice president now owns 5,396 shares of the company’s stock, valued at approximately $748,155.40. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 40.50% of the company’s stock.
Several large investors have recently modified their holdings of TSRO. Botty Investors LLC acquired a new stake in shares of TESARO during the second quarter worth about $140,000. Meeder Asset Management Inc. acquired a new stake in shares of TESARO during the first quarter worth about $177,000. Oppenheimer Asset Management Inc. increased its stake in shares of TESARO by 3,042.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 1,430 shares during the last quarter. BB&T Securities LLC acquired a new stake in shares of TESARO during the second quarter worth about $222,000. Finally, Fox Run Management L.L.C. acquired a new stake in shares of TESARO during the second quarter worth about $224,000.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.